Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

Original Article

N.D. Gross, D.M. Miller, N.I. Khushalani, V. Divi, E.S. Ruiz, E.J. Lipson, F. Meier, Y.B. Su, P.L. Swiecicki, J. Atlas, J.L. Geiger, A. Hauschild, J.H. Choe, B.G. Hughes, D. Schadendorf, V.A. Patel, J. Homsi, J.M. Taube, A.M. Lim, R. Ferrarotto, H.L. Kaufman, F. Seebach, I. Lowy, S.-Y. Yoo, M. Mathias, K. Fenech, H. Han, M.G. Fury, and D. Rischin

N Engl J Med 2022;387:1557-1568

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
10/26/2022
Course expires: 
10/27/2024

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation